DEFA14A 1 d445139ddefa14a.htm DEFA14A DEFA14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material Pursuant to §240.14a-12

Alnylam Pharmaceuticals, Inc.

                                                                                                                                                                                                                                                                                                                           

(Name of Registrant as Specified in Its Charter)

 

                                                                                                                                                                                                                                                                                                                           

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

No fee required.

 

Fee paid previously with preliminary materials.

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.


                                  
                        
   

 

Your Vote Counts!

          
 

 

ALNYLAM PHARMACEUTICALS, INC.

 

    2023 Annual Meeting    

Vote by May 17, 2023 11:59 PM ET. For shares held in a 401(k) Plan, vote by May 15, 2023 11:59 PM ET.

             
     

 

ALNYLAM PHARMACEUTICALS, INC.

ATTN: SECRETARY

675 WEST KENDALL STREET

HENRI A. TERMEER SQUARE

CAMBRIDGE, MA 02142

 

LOGO                         

 

   

    

 

   

    

     
 
 
              
 
 

V05850-P87422-Z84413

                                       
            

You invested in ALNYLAM PHARMACEUTICALS, INC. and it’s time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on May 18, 2023.

Get informed before you vote

View the Proxy Statement, Annual Report on Form 10-K and Annual Report to Stockholders online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 4, 2023. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

 

LOGO

    *Please check the meeting materials for any special requirements for meeting attendance.

V1.1


Vote at www.ProxyVote.com

 

 

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

 

    Voting Items   Board
Recommends
 

1.

 

To elect the following nominees as Class I directors of Alnylam:

 

Nominees:

 

1a.

 

 

Michael W. Bonney

  LOGO  For
 

1b.

  Yvonne L. Greenstreet, MBChB, MBA   LOGO  For
 

1c.

  Phillip A. Sharp, Ph.D.   LOGO  For
 

1d.

  Elliott Sigal, M.D., Ph.D.   LOGO  For
 

2.

  To approve, in a non-binding advisory vote, the compensation of Alnylam’s named executive officers.   LOGO  For
 

 

3.

 

 

To recommend, in a non-binding advisory vote, the frequency of advisory stockholder votes on executive compensation.

  LOGO  Year
 

 

4.

 

 

To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam’s independent auditors for the fiscal year ending December 31, 2023.

  LOGO  For

In their discretion, the Proxies are authorized to vote upon any other business that may properly come before the annual meeting or at any adjournment(s) thereof.

 

 

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Sign up for E-delivery”.

                                                             V05851-P87422-Z84413